Commercial-Scale Recombinant Proteins CDMOs
Recombinant Proteins manufacturers on CDMO Signal: 11 listed, 11 with a Signal Score. Together they have 40 FDA inspections on file (including 12 NAI, 26 VAI and 2 OAI), 2 FDA warning letters and 139 EMA/MHRA GMP certificates. Fewer than three are fully evidenced (all four score pillars and at least one ClinicalTrials.gov match), so this page does not name a top three. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.
Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.
Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 12 NAI (no action), 26 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Denmark (52), Germany (33), United States (31), UNITED KINGDOM (17), Lithuania (8).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 2 |
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
|
86.7 | 100.0 | 0 insp · 35 GMP | None on file | — | |
| 3 |
KB
|
84.1 | 98.5 | 2 insp · 1 GMP | 2026-04-01 · VAI | Limited | — |
| 4 |
WK
Jena, DE · Amsterdam, NL · San Diego, CA
|
82.9 | 100.0 | 1 insp · 13 GMP | 2023-12-07 · VAI | — | — |
| 5 |
RB
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | None on file | — | — |
| 6 |
NW
|
80.8 | 100.0 | 0 insp · 8 GMP | None on file | Available | — |
| 7 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 8 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 9 |
Oklahoma City, OK
|
78.6 | 98.2 | 1 insp · 0 GMP | 2026-06-17 · VAI | Available | — |
| 10 |
RB
|
77.8 | 99.2 | 2 insp · 2 GMP | 2025-01-17 · VAI | — | — |
| 11 |
|
76.1 | 77.3 | 24 insp · 39 GMP | 2026-05-22 · VAI Warning letter 2025-11-20 |
— | — |